Iranian Society of Gynecology Oncology

Document Type : Original Research Article


Department of Obstetrics and Gynecology, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran


Background and objective: Current study was conducted to determine the effects of Oxytocin drip on operative blood loss and fluid overload during hysteroscopy.
Materials and Methods: In this double-blind randomized clinical trial, 54 women with abnormal uterine bleeding who were candidates for hysteroscopy were consecutively enrolled and randomly assigned to receive either oxytocin or normal saline and the alterations in serum hemoglobin, sodium, albumin, and hematocrit were compared between two groups.
Results: The results demonstrated that alterations in serum hemoglobin, sodium, albumin, and hematocrit did not significantly differ between the two groups (P < /em>>0.05).
Conclusion: It seems using oxytocin drip during hysteroscopy in patients with intrauterine lesions would have no effect on operative blood loss and fluid overload.


Main Subjects


Hysteroscopy is a common diagnostic procedure which is done to detect abnormal uterine conditions such as fibromas, intrauterine adhesions, polyps, intrauterine septum, and other congenital uterine anomalies (1, 2).Intrauterine fibromas, adhesions, and polyps may be resected by surgical hysteroscopy and the congenital anomalies and abnormal uterine bleedings may be diagnosed and treated by this exam (3).
Abnormal uterine bleeding (AUB) is a common complaint in women of reproductive age. In treatment-resistant ABU cases, it is recommended to perform an endometrial biopsy, transvaginal ultrasonography, hysteroscopy, and D&C (dilation and curettage) (4, 5).
One challenge that the surgeons face during endometrial hysteroscopy is the patient's blood loss which may be due to poor technical performance, presence of other intrauterine lesions, and loss of accumulated blood during endometrial resection (12, 13).
Evidences showed that preventive approaches by GnRH agonists and intracervical vasopressin injection may reduce the blood loss volume during surgery and systemic absorption of glycine during uterine resection by hysteroscopy (14-16).
To our knowledge, few studies were done in this area. Accordingly, in this study, the effect of oxytocin drip during hysteroscopy in patients with intrauterine lesions was evaluated on operative blood loss and fluid overload.


Materials and Methods

This double-blind randomized clinical trial was conducted on 54 consecutive women with abnormal uterine bleeding who were candidates for hysteroscopy for resection of fibroma or polyp (diagnosed by transvaginal ultrasonography) at Yas Hospital in 2012.
The inclusion criteria were menorrhagia and the existence of polyps and fibromas resistance to medical treatments. Patients with diabetes mellitus, severe medical background disease, pregnancy over 12 weeks, symptoms of endometriosis, and pelvic inflammatory disease and who might not tolerate sterility, were excluded.
This research was done in compliance with the Helsinki Declaration and was approved by the local ethics committee (IR.TUMS.MEDICINE.REC.1392.30.1431). All the patients signed an informed consent.
All patients were admitted one day before operation and the serum hemoglobin, hematocrit, sodium, and albumin were checked in them. Spinal anesthesia was performed for all patients. Hysteroscopy was performed by Karl-Storz instrument and the resectoscope was Karl-Storz number 12 with an Olympus camera of 8 mm diameter. Dilatation was performed up to 9 Hegar and the fluid flow rate was 300 to 450 mL per minute with distension pressure between 90 and 130 mmHg.
The subjects were randomly (by stratified block randomization) assigned to receive either oxytocin (including five Caspian tamin Pharmaceutical Company oxytocin vials containing 50 unit per mL per vial added in 500-mL ringer-lactate serum administered during surgery) or normal saline (as placebo with similar form and administration patterns) 15 minutes before the surgery with an infusion rate of 227 milli-unit per minute and the infusion stopped exactly after the termination of the operation. Then the alteration in serum hemoglobin, sodium, and hematocrit was compared between two groups (each group including 27 subjects) till 12 hours after the operation.
The entering fluid was measured but exiting fluid and central venous pressure (CVP) were not measured. The patients in the two groups were matched for confounding variables.
Data analysis was performed by SPSS software version 13 (SPSS Inc., Chicago, IL., USA). Independent-sample-T, Fisher, and Repeated-Measure ANOVA tests were used and were considered statistically significant at P-values less than 0.05.
To ensure the reliability of the questionnaire on demographic, pregnancy, and childbirth characteristics, the concurrent evaluation method was applied. Initially, the information form was completed simultaneously by the researcher and an assistant in the research environment for 10 qualified units, and then the correlation coefficients were calculated between the small variables determined by examination.
To describe the descriptive variables of the study, the central indicators and data distribution and frequency were used. Afterwards, to compare the quantitative variables with normal distribution and homogeneity of variances, an independent t-test was applied between the two groups. In cases of abnormal distribution, the Mann-Whitney U test was used. To compare and relate the quantitative and qualitative variables between the groups, the chi-square test and one-way ANOVA (Tukey) were used, respectively. In all calculations, P-value<0.05 was considered as the significance level.


The frequency distribution of age, previous pregnancies, durations of normal vaginal deliveries and cesarean sections, and abortions were matched across the groups (Table 1). In addition, the intraoperative and ultrasonographic findings were alike between the two groups (Table 2).

The hysteroscopy exams were indicative of polyp in 44.4% and fibroma in 55.6% in both groups (P>0.05). There was no significant difference between the two groups from points of change in serum levels of hemoglobin, hematocrit, sodium, and albumin (Table 3)

Table 1. Frequency distribution of age and previous gestational history among participants

Variables Group Mean Standard Deviation
Age Oxytocin 36.4 5.9
Placebo 36.3 7.6
Gravid Oxytocin 2.4 1.4
Placebo 2.4 1.3
Previous NVD times Oxytocin 1.1 1.1
Placebo 1.3 1.3
Previous C/Section times Oxytocin 0.7 0.8
Placebo 0.6 0.8
Previous Abortion times Oxytocin 0.6 0.7
Placebo 0.4 0.7

NVD: Normal Vaginal Delivery, C/Section: Cesarean Section. There was no significant difference between two groups for all mentioned variables (P-value> 0.05).
Table 2. Frequency distribution of intraoperative and ultrasonography findings among participants

Variables Group Mean Standard Deviation
Uterine Size Oxytocin 88.4 12.9
Placebo 81.8 9.9
Endometrial Thickness Oxytocin 10 2.2
Placebo 9.5 1.9
Operation Time Oxytocin 37.2 15.3
Placebo 44.4 16.2
Glycine Amount Oxytocin 2825.9 1956.5
Placebo 3079.6 1905.1
Size in Ultrasound Oxytocin 22.2 10.5
Placebo 29.3 9.1
Size in Surgery Oxytocin 25.4 9.2
Placebo 27.8 10.1

There was no significant difference between two groups for all mentioned variables (P-value> 0.05).
Table 3. Frequency distribution of serum hemoglobin, hematocrit, sodium and albumin levels among participants

Variables Group Pre-
1 hour after surgery 6 hours
12 hours
Hemoglobin Oxytocin 11.7±0.8 11.3±0.9 11±0.9 10.9±0.9
Placebo 12.2±0.8 11.8±0.7 11.1±0.9 10.7±0.9
Hematocrit Oxytocin 35.6±2.1 34.6±2.3 33.9±2.8 33.5±2.9
Placebo 36.2±1.9 35.5±2 34.2±2.2 33.8±2.3
Sodium Oxytocin 142.5±2.3 141±3.9 139.7±3.3 139.5±1.9
Placebo 142.8±2.5 141.3±2.1 139.6±2.6 138.7±2.9
Albumin Oxytocin 4.5±0.3 4.3±0.3 4.2±0.3 4.1±0.3
Placebo 4.5±0.3 4.3±0.3 4.1±0.3 4.1±0.3

There was no significant difference between two groups for all mentioned variables (P value> 0.05).




The results demonstrated that alterations in serum hemoglobin, sodium, albumin, and hematocrit levels did not significantly differ between the two groups. However, no drug adverse reaction was seen in the two groups except one case of pulmonary edema in the oxytocin group. A study by Shokeir et al. in Egypt in 2011 (17), revealed that the mean fluid-related distension amount and the mean duration of surgery did not differ across the oxytocin and placebo group. Also, serum albumin, ethanol, sodium, Glycine, and hematocrit despite lower status in the oxytocin group, were not significantly different. Demographic data, uterine size, endometrial thickness, and resected tissue weight were alike across the groups. In total, their results showed no differences between oxytocin and placebo injection as well as our study.
In a study by Sherif Abdo Mousa and colleagues (18), oxytocin and Tran examine acid were compared among women under myomectomy by hysteroscopy and the results demonstrated that hemoglobin had more reduction in the tranexamic acid receiving group compared with the oxytocin group. Also, the heart rate was lower in the tranexamic acid group. Wang et al. (19) in 2007, evaluated women under laparoscopic myomectomy and compared those with and without oxytocin administration and found that blood loss and blood transfusion amounts were significantly lower in the oxytocin group.
A meta-analysis published by Kongnyuy et al. in 2011 (20) reported no additional effect for oxytocin in the reduction of blood loss in patients under myomectomy. However, also seen in our study, no additional side effects were seen in patients who received oxytocin.





Overall, according to the obtained results, it may be concluded that using oxytocin drip during hysteroscopy in patients with intrauterine lesions would have no effect on operative blood loss and fluid overload. However, further studies, with larger sample size and modification of confounding factors, are required to obtain more definite results. Also, evaluating other therapeutics is suggested in order to reduce blood loss during hysteroscopy.





The authors thank all those who helped them writing this article.


Conflicts of Interest

Authors declared no conflict of interests.


1. Clark TJ, Voit D, Gupta JK, Hyde C, Song F, Khan KS. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. Jama. 2002;288(13):1610-21. [DOI:10.1001/jama.288.13.1610] [PMID]
2. Polyzos NP, Zavos A, Valachis A, Dragamestianos C, Blockeel C, Stoop D, Papanikolaou EG, Tournaye H, Devroey P, Messinis IE. Misoprostol prior to hysteroscopy in premenopausal and post-menopausal women. A systematic review and meta-analysis. Hum Reprod update. 2012;18(4):393-404. [DOI:10.1093/humupd/dms014] [PMID]
3. Yang JH, Chen MJ, Wu My, Chao KH, Ho HN, Yang YS. Office hysteroscopic early lysis of intrauterine adhesion after transcervical resection of multiple apposing submucous myomas. Fertil Steril 2008; 89(5):1254-9. [DOI:10.1016/j.fertnstert.2007.05.027] [PMID]
4. Deckardt R, Lueken RP, Gallinat A, Moller CP, et al. Comparison of transvaginal ultrasound, hysteroscopy, and dilation and curettage in diagnosis of abnormal vaginal bleeding and intrauterine pathology in perimenopausal and postmenopausal women. J Am Assoc Gynecol Laparosc 2002; 9: 2273- 8. [DOI:10.1016/S1074-3804(05)60404-5]
5. Galle PC, Mc Rae MA. Abnormal uterine bleeding finding & treating the cause. Postyrad Med 1993; 93:73-6, 80-1. [DOI:10.1080/00325481.1993.11701599] [PMID]
6. Mihm LM Quick VA, Brumfield JA, Connors AF Jr&et al. The accuracy of endometrial biopsy and saline sonohysterography in the determination of the cause of abnormal uterine bleeding. Am J obstet Gynecol 2002; 186: 858-60. [DOI:10.1067/mob.2002.123056] [PMID]
7. Istre O, Qvigstad E. Currrent treatment options for abnormal uterine bleeding: an evidence-based approach. Best Pract Res Clin Obstet Gynecol. 2007; 21:905-13. [DOI:10.1016/j.bpobgyn.2007.03.021] [PMID]
8. Vilos GA. Hysteroscopic and nonhysteroscopic endometrial ablation. Obstet Gynecol Clin North Am. 2004; 31:687-704. [DOI:10.1016/j.ogc.2004.05.009] [PMID]
9. Hill DA. Abnormal uterine bleeding: avoid the rush to hysterectomy. J Fam Pract. 2009; 58:136-42.
10. Chen EC, Danis PG,Tweed E. Clinical inquiries. Menstrual disturbances in perimenopausal women: what's best? J Fam Pract. 2009; 58:E3.
11. Penninx JP, Mol BW, Bongers MY. Endometrial ablation with paracervical block. J Reprod Med. 2009; 54:617-620.
12. Brun JL, Raynal J, Burlet G, Galand B, Quereux C, Bernard P. Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: The French, multicenter, randomized study. J Minim Invasive Gynecol. 2006; 13:424-30. [DOI:10.1016/j.jmig.2006.05.006] [PMID]
13. Papadopoulos NP, Magos A. First-generation endometrial ablation: roller-ball vs loop vs laser. Best Pract Res Clin Obstet Gynaecol. 2007; 21:915-29. [DOI:10.1016/j.bpobgyn.2007.03.014] [PMID]
14. Bongers MY, Mol BW, Br€olmann HA. Current treatment of dysfunctional uterine bleeding. Maturitas. 2004;47:159-74. [DOI:10.1016/j.maturitas.2003.08.002] [PMID]
15. Goldenberg M, Zolti M, Bider D, Et shin A, Sela B, Seidman DS. The effect of intracervical vasopressin on the systemic absorption of glycine during hysteroscopic endometrial ablation. Obstet Gynecol. 1996;87: 1025-9. [DOI:10.1016/0029-7844(96)00063-4]
16. Corson SL, Brooks PG, Serden SP, Batzer FR, Gocial B. Effects of vasopressin administration during hysteroscopic surgery. J Reprod Med. 1994;39:419-23.
17. Shokeir T, lakkany N-E, Sadek E, El-shamy M, and Hashim H.A: An RCT: Use of Oxytocin Drip during Hysteroscopic Endometrial Resection and Its Effect on Operative Blood Loss and Glycine Deficit. J Minim Invasive Gynecol. 2011: 18 (4);489-494 [DOI:10.1016/j.jmig.2011.03.015] [PMID]
18. Mousa SA Yassen AM, Alhadary HS, Sadek ES, Hady E AH. Hematological profile and transfusion requirement during hysteroscopic myomectomy: A comparative study between oxytocin and tranexamic acid infusion; Egypt J Anaesth. 2012; 1-8. [DOI:10.1016/j.egja.2011.12.003]
19. Wang CJ, Lee CL, Yuen LT, Kay N, Han CM, Soong YK. Oxytocin infusion in laparoscopic myomectomy may decrease operative blood loss. J Minim Invasive Gynecol. 2007 Mar 1;14(2):184-8. [DOI:10.1016/j.jmig.2006.09.016] [PMID]
20. Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database Syst Rev. 2014(8). [DOI:10.1002/14651858.CD005355.pub5] [PMID]